RC
RCUS.US Arcus Biosciences Inc
- Market cap
- USD 2.36B
- P/E
- -
- P/B
- 6.78x
- ROE
- -129.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RCUS.US undervalued?
Graham numberThe Graham number of Arcus Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arcus Biosciences Inc fundamental analysis
No fundamental analysis for Arcus Biosciences Inc yet.
Arcus Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor…
Full company profileArcus Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arcus Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 1.41M | 8.35M | 15.0M | 78.0M | 383M | 112M | 117M | 258M | 247M | 89.3M |
| Gross Profit | -1.31M | 1.41M | 8.35M | 15.0M | 78.0M | 383M | 112M | 117M | 258M | 237M | 86.7M |
| Operating Income | -18.2M | -53.4M | -54.9M | -88.7M | -124M | 54.0M | -280M | -340M | -330M | -386M | -481M |
| EBITDA | -16.9M | -50.8M | -51.2M | -85.1M | -120M | 59.0M | -258M | -291M | -269M | -335M | -441M |
| Net Income | -18.0M | -53.1M | -49.6M | -75.9M | -123M | 53.0M | -267M | -307M | -283M | -353M | -463M |
| EPS | -0.73 | -2.16 | -1.43 | -1.73 | -2.25 | 0.72 | -3.71 | -4.15 | -3.14 | -3.29 | -3.63 |
| Balance Sheet | |||||||||||
| Total Assets | 110M | 190M | 275M | 203M | 772M | 1.59B | 1.35B | 1.10B | 1.15B | 1.14B | 818M |
| Total Liabilities | 10.2M | 36.6M | 40.0M | 39.3M | 270M | 750M | 688M | 633M | 665M | 508M | 460M |
| Shareholders' Equity | 99.5M | 154M | 235M | 164M | 502M | 841M | 657M | 462M | 485M | 631M | 358M |
| Cash & Short-term Investments | 98.9M | 176M | 257M | 188M | 729M | 499M | 1.01B | 759M | 978M | 981M | 630M |
| Total Debt | - | - | - | - | 18.1M | 122M | 120M | 11.0M | 60.0M | 112M | 116M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.9M | -25.1M | -43.0M | -73.5M | 111M | -256M | 438M | -306M | -170M | -482M | -460M |
| Capital Expenditure | 4.10M | 5.51M | 3.74M | 1.93M | 3.06M | 26.1M | 6.00M | 24.0M | 6.00M | 2.00M | 0.00 |
| Free Cash Flow | -17.0M | -30.6M | -46.7M | -75.4M | 108M | -282M | 432M | -330M | -176M | -484M | -460M |
| Ratios | |||||||||||
| ROE | -18.1% | -34.5% | -21.1% | -46.3% | -24.5% | 6.3% | -40.6% | -66.5% | -58.4% | -55.9% | -129.2% |
| ROA | -16.4% | -27.9% | -18.0% | -37.4% | -15.9% | 3.3% | -19.9% | -28.0% | -24.6% | -31.0% | -56.6% |
| Net Profit Margin | - | -3,756.7% | -593.7% | -506.2% | -157.7% | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% | -517.9% |
| Debt to Equity | - | - | - | - | 0.04x | 0.14x | 0.18x | 0.02x | 0.12x | 0.18x | 0.32x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Arcus Biosciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 5.00M | 0.07 | 9.4% |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Arcus Biosciences Inc
- Insiders 25.47%
- Institutions 67.77%
- Public & others 6.76%
- Shares outstanding 144M
- Free float 107M
Top funds holding RCUS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 6.30M | 4.38% | -0.16% | Oct 2026 |
| Vanguard Health Care Inv | 3.45M | 2.39% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.82M | 1.96% | +0.44% | Sep 2026 |
| iShares Russell 2000 ETF | 2.28M | 1.59% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.22M | 1.54% | +2.69% | Oct 2026 |
| Vanguard Small Cap Index | 1.00M | 0.70% | -0.83% | Sep 2026 |
| Fidelity Small Cap Index | 980K | 0.68% | +0.16% | Aug 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 954K | 0.66% | -0.05% | Oct 2026 |
| Invesco S&P SmallCap Momentum ETF | 893K | 0.62% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 853K | 0.59% | 0.00% | Aug 2026 |
| Fidelity Small Cap Growth | 809K | 0.56% | 0.00% | Aug 2026 |
| Belfius Equities Cure C Cap | 791K | 0.55% | 0.00% | Apr 2026 |
| BNP Paribas US Small Cap ClassicC | 752K | 0.52% | -10.85% | Sep 2026 |
| BGF World Healthscience A2 | 729K | 0.51% | 0.00% | Jul 2026 |
| iShares Biotechnology ETF | 662K | 0.46% | -0.19% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 659K | 0.46% | -0.38% | Oct 2026 |
| abrdn Healthcare Investors | 611K | 0.42% | +169.65% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 597K | 0.41% | 0.00% | Oct 2026 |
| BlackRock Health Sciences Opps Inv A | 572K | 0.40% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 559K | 0.39% | -3.65% | Sep 2026 |
Top institutions holding RCUS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 16.4M | 11.40% | +7.81% | Jun 2026 |
| State Street Corp | 6.03M | 4.19% | +11.39% | Jun 2026 |
| Wellington Management Company LLP | 5.90M | 4.09% | -3.19% | Jun 2026 |
| Suvretta Capital Management, LLC | 4.78M | 3.32% | -5.06% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.48M | 3.11% | +4.76% | Jun 2026 |
| FMR Inc | 4.05M | 2.81% | +247.54% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.89M | 2.70% | +0.82% | Jun 2026 |
| Citadel Advisors Llc | 3.14M | 2.18% | +135.73% | Jun 2026 |
| Woodline Partners LP | 3.01M | 2.09% | -20.38% | Jun 2026 |
| Geode Capital Management, LLC | 2.45M | 1.70% | +8.72% | Jun 2026 |
| Siren, L.L.C. | 2.42M | 1.68% | -19.51% | Jun 2026 |
| Fisher Asset Management, LLC | 2.14M | 1.49% | -2.33% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.95M | 1.35% | -48.29% | Jun 2026 |
| Samlyn Capital, LLC | 1.55M | 1.07% | -18.93% | Jun 2026 |
| BNP Paribas Investment Partners SA | 1.42M | 0.99% | -14.21% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.39M | 0.97% | -3.04% | Sep 2026 |
| The Goldman Sachs Group Inc | 1.39M | 0.96% | +38.79% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.17M | 0.81% | +158.58% | Jun 2026 |
| Aberdeen Group PLC | 1.06M | 0.73% | +62.39% | Sep 2026 |
| Sofinnova Ventures | 946K | 0.66% | +2.45% | Jun 2026 |
Arcus Biosciences Inc company profile
- Company name
- Arcus Biosciences Inc
- Ticker
- RCUS.US
- Exchange
- USA Stocks
- Listed since
- Mar 15, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 601
- Fiscal year end
- December
- Address
- 3928 Point Eden Way, Hayward, CA, United States, 94545
- Phone
- 510 694 6200
- Website
- arcusbio.com
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Arcus Biosciences Inc management
10- Dr. Terry J. Rosen Ph.D.Co-Founder, Chairman & CEO · born 1960
- Dr. Juan Carlos Jaen Ph.D.Co- Founder & President · born 1958
- Mr. Robert C. Goeltz IIPrincipal Financial Officer & CFO · born 1973
- Dr. Richard A. Markus M.D., Ph.D.Chief Medical Officer
- Dr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory Board
- Mr. Alexander Azoy CPAChief Accounting Officer · born 1976
- Dr. Jonathan Yingling Ph.D.Chief Scientific Officer · born 1969
- Pia EavesVice President of Investor Relations & Strategy
- Ms. Carolyn C. Tang J.D.General Counsel & Corporate Secretary · born 1979
- Holli KolkeyVice President of Corporate Communications